<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02733614</url>
  </required_header>
  <id_info>
    <org_study_id>AVN010</org_study_id>
    <nct_id>NCT02733614</nct_id>
  </id_info>
  <brief_title>Proof-of-concept Study to Assess the Efficacy and Safety of SRX246 in Adults With PTSD</brief_title>
  <official_title>A Proof of Concept (POC) Clinical Trial for Post-Traumatic Stress Disorder (PTSD) With a First-In-Class Vasopressin 1a Receptor Antagonist (SRX246)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azevan Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>U.S. Army Medical Research and Materiel Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Azevan Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      18-week, crossover, double-blind, randomized, placebo controlled proof-of-concept study to
      assess the efficacy and safety of SRX246 (160 mg bid) vs placebo in 52 adult veterans and
      civilians with a primary diagnosis of PTSD. Subjects will be randomly assigned in a
      double-blind fashion to 2 groups in a crossover design. The first group will receive SRX246
      for 8 weeks followed by 8 weeks of placebo, while the second group will receive placebo for 8
      weeks followed by 8 weeks of SRX246. Both groups will engage in a 7-day washout period
      between treatments. Subjects will be assessed at baseline and then every 2 weeks during the
      trial using the CAPS.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of overall clinical improvement</measure>
    <time_frame>18 weeks</time_frame>
    <description>Measured using the Clinician Administered PTSD Scale (CAPS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events</measure>
    <time_frame>18 weeks</time_frame>
    <description>Assessments of adverse events (AEs), dose reductions and dropouts due to AEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in depressive symptoms</measure>
    <time_frame>18 weeks</time_frame>
    <description>Measured using the Beck Depression Inventory (BDI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in anger and aggression</measure>
    <time_frame>18 weeks</time_frame>
    <description>Measured using the Overt Aggression Scale-Modified (OAS-M)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in irritability</measure>
    <time_frame>18 weeks</time_frame>
    <description>Measured using the Sheehan Irritability Scale (SIS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in overall functioning</measure>
    <time_frame>18 weeks</time_frame>
    <description>Measured using the Medical Outcomes Study Short-Form 12-Item Health Survey (SF-12)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in quality of life</measure>
    <time_frame>18 weeks</time_frame>
    <description>Measured using the Sheehan Disability Scale (SDS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in sleep quality</measure>
    <time_frame>18 weeks</time_frame>
    <description>Measured using the Pittsburgh Sleep Quality Index (PSQI)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>PTSD</condition>
  <arm_group>
    <arm_group_label>SRX246</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SRX246 160 mg BID, oral administration, capsules, daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>oral administration, capsules, daily for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SRX246</intervention_name>
    <description>novel V1a receptor antagonist</description>
    <arm_group_label>SRX246</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Medically stable, current diagnosis of PTSD

        Exclusion Criteria:

          -  Medically unstable
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andrew McAleavey, PhD</last_name>
    <phone>212-821-0711</phone>
    <email>anm9256@med.cornell.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Neal G Simon, PhD</last_name>
    <phone>610-419-1057</phone>
    <email>ngsimon@azevan.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew McAleavey, PhD</last_name>
      <phone>212-821-0711</phone>
      <email>anm9256@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>JoAnn Difede, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2016</study_first_submitted>
  <study_first_submitted_qc>April 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2016</study_first_posted>
  <last_update_submitted>June 20, 2017</last_update_submitted>
  <last_update_submitted_qc>June 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>SRX246</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

